This content is from: China (PRC)

Pharma companies want clarity on supplementary data in China

Despite the Supreme Court’s proposal to lower the bar for post-filing patent data, innovators are sceptical that the provisions will have real impact

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial